Jefferies initiated coverage of Damora Therapeutics (DMRA) with a Buy rating and $50 price target. The company’s lead asset DMR-001 is a half-life extended anti-mutCALR monoclonal antibody, the analyst tells investors in a research note. The firm believes DMR-001 could differentiate from Incyte’s (INCY) INCA-989 through potentially better efficacy in type 2 patients and more conveinient dosing. It models $2.2B peak sales for DMR-001.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on DMRA:
Disclaimer & DisclosureReport an Issue
